Update on nonsmall cell lung cancer

European Respiratory Review

Volumn 19, Issue 117, 2010, Pages 173-185

  Zalcman, G ^a   Bergot, E ^a   Lechapt, E ^b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CHU CÔTE DE NACRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARQ 197; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELDERLY CARE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG VOLUME; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; QUALITY OF LIFE; RADIATION PNEUMONIA; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SMOKING; SURVIVAL TIME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS;

EID: 78349252895     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00006610     Document Type: Article

References (120)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931-991.
3. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-299.
4. Depierre A, Lagrange JL, Theobald S, et al. Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000). Br J Cancer 2003; 89: Suppl. 1, S35-S49.
5. Friedel G, Steger V, Kyriss T, et al. Prognosis in N2 NSCLC. Lung Cancer 2004; 45: Suppl. 2, S45-S53.
6. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer f1 cm in size: a review of SEER data. Chest 2010 [Epub ahead of print DOI: 10.1378/chest.09-2547].
7. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559.
8. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28: 35-42.
9. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbineplus cisplatin versus observation in patients with completelyresected stage IB-IIIA non-small-cell lung cancer (AdjuvantNavelbine International Trialist Association (ANITA)): a rando-mised controlled trial. Lancet Oncol 2006; 7: 719-727.
10. Burdett S, Stewart LA, Rydzewska L. A systematic review andmeta-analysis of the literature: chemotherapy and surgery versussurgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1: 611-621.
11. Berghmans T, Paesmans M, Meert AP, et al. Survival improve-ment in resectable non-small cell lung cancer with (neo)adjuvantchemotherapy: results of a meta-analysis of the literature. LungCancer 2005; 49: 13-23.
12. Westeel V, Milleron BJ, Quoix EA, et al. Long-term results of theFrench randomized trial comparing neoadjuvant chemotherapyfollowed by surgery versus surgery alone in resectable non-smallcell lung cancer. J Clin Oncol 2010; 28, Suppl., 15s, abstract 7003.
13. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
14. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
15. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomizedcontrolled trial of resection versus radiotherapy after inductionchemotherapy in stage IIIA-N2 non-small-cell lung cancer. J NatlCancer Inst 2007; 99: 442-450.
16. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy pluschemotherapy with or without surgical resection for stage IIInon-small-cell lung cancer: a phase III randomised controlledtrial. Lancet 2009; 374: 379-386.
17. Meert AP, Martin B, Delmotte P, et al. The role of EGF-Rexpression on patient survival in lung cancer: a systematicreview with meta-analysis. Eur Respir J 2002; 20: 975-981.
18. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
19. Rosell R, Moran T, Queralt C, et al. Screening for epidermalgrowth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
20. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatinplus docetaxel in patients with non-small-cell lung cancerharbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial. LancetOncol 2010; 11: 121-128.
21. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin aloneor with bevacizumab for non-small-cell lung cancer. N Engl JMed 2006; 355: 2542-2550.
22. Mok TS, Ramalingam SS. Maintenance therapy in nonsmall-celllung cancer: a new treatment paradigm. Cancer 2009; 115:5143-5154.
23. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advancednon-small-cell lung cancer in the elderly: results of an interna-tional expert panel. J Clin Oncol 2005; 23: 3125-3137.
24. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
25. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy ofgemcitabine plus platinum chemotherapy compared with otherplatinum containing regimens in advanced non-small-cell lungcancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47: 69-80.
26. Douillard JY, Laporte S, Fossella F, et al. Comparison ofdocetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;2: 939-946.
27. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib incombination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784.
28. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combinationwith paclitaxel and carboplatin in advanced non-small-celllung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794.
29. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study oferlotinib in combination with cisplatin and gemcitabine inadvanced non-small-cell lung cancer: the Tarceva Lung CancerInvestigation Trial. J Clin Oncol 2007; 25: 1545-1552.
30. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trialof erlotinib hydrochloride (OSI-774) combined with carboplatinand paclitaxel chemotherapy in advanced non-small-cell lungcancer. J Clin Oncol 2005; 23: 5892-5899.
31. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase IIItrial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J ClinOncol 2004; 22: 1589-1597.
32. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III studycomparing cisplatin plus gemcitabine with cisplatin pluspemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 21:3543-3551.
33. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy ofpemetrexed according to NSCLC histology: a review of twophase III studies. Oncologist 2009; 14: 253-263.
34. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma ofthe lung compared with other histotypes shows higher messen-ger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-1596.
35. Grilley-Olson JE, Hayes DN, Qaqish BF, et al. Diagnosticreproducibility of squamous cell carcinoma (SC) in the era ofhistology-directed non-small cell lung cancer (NSCLC) chemo-therapy: a large prospective study. J Clin Oncol 2009; 27: Suppl.,409s, abstract 8008.
36. Scagliotti GV, Ceppi P, Novello S, et al. Chemotherapy treatmentdecisions in advanced non-small cell lung cancer based onhistology. J Clin Oncol 2009; 27: Suppl. 15s, 431-435.
37. Downey P, Cummins R, Moran M, et al. If it's not CK5/6positive, TTF-1 negative it's not a squamous cell carcinoma oflung. APMIS 2008; 116: 526-529.
38. Boelens MC, van den Berg A, Vogelzang I, et al. Differentialexpression and distribution of epithelial adhesion molecules innon-small cell lung cancer and normal bronchus. J Clin Pathol 2007; 60: 608-614.
39. Savci-Heijink CD, Kosari F, Aubry MC, et al. The role ofdesmoglein-3 in the diagnosis of squamous cell carcinoma of thelung. Am J Pathol 2009; 174: 1629-1637.
40. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker ofsquamous differentiation in undifferentiated large-cell carci-noma of the lung. Mod Pathol 2009; 22: 709-717.
41. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay basedon hsa-miR-205 expression distinguishes squamous from non-squamous non-small-cell lung carcinoma. J Clin Oncol 2009; 27:2030-2037.
42. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomizedtrial of docetaxel versus best supportive care in patients withnon-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
43. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18: 2354-2362.
44. Shepherd FA, Fossella FV, Lynch T, et al. Docetaxel (Taxotere)shows survival and quality-of-life benefits in the second-linetreatment of non-small cell lung cancer: a review of two phase IIItrials. Semin Oncol 2001; 28: Suppl. 2, 4-9.
45. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trialof two docetaxel regimens (weekly vs 3 week) in the second-linetreatment of non-small-cell lung cancer. The DISTAL 01 study.Br J Cancer 2004; 91: 1996-2004.
46. Ramlau R, Gervais R, Krzakowski M, et al. Phase III studycomparing oral topotecan to intravenous docetaxel in patientswith pretreated advanced non-small-cell lung cancer. J ClinOncol 2006; 24: 2800-2807.
47. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib inpreviously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132.
48. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus bestsupportive care in previously treated patients with refractoryadvanced non-small-cell lung cancer: results from a randomised,placebo-controlled, multicentre study (Iressa SurvivalEvaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
49. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer -molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144.
50. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel inpreviously treated non-small-cell lung cancer (INTEREST): arandomised phase III trial. Lancet 2008; 372: 1809-1818.
51. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictorsof outcome with gefitinib and docetaxel in previously treatednon-small-cell lung cancer: data from the randomized phase IIIINTEREST trial. J Clin Oncol 2009; 28: 744-752.
52. Zalcman G, Bergot E. Gefitinib plus docetaxel in non-small-celllung cancer. Lancet 2009; 373: 541.
53. Keith RL, Miller YE, Gemmill RM, et al. Angiogenic squamousdysplasia in bronchi of individuals at high risk for lung cancer.Clin Cancer Res 2000; 6: 1616-1625.
54. Delmotte P, Martin B, Paesmans M, et al. VEGF et survie despatients atteints d'un cancer pulmonaire: revue systématiqueavec méta-analyse [VEGF and survival of patients with lungcancer: a systematic literature review and meta-analysis]. RevMal Respir 2002; 19: 577-584.
55. Saintigny P, Besse B, Callard P, et al. Erythropoietin anderythropoietin receptor coexpression is associated with poorsurvival in stage I non-small cell lung cancer. Clin Cancer Res 2007; 13: 4825-4831.
56. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation ofthe clinical and radiographic risk factors associated with severepulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxelplus bevacizumab. J Clin Oncol 2009; 27: 1405-1412.
57. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatinplus gemcitabine with either placebo or bevacizumab as first-linetherapy for nonsquamous non-small-cell lung cancer: AVAil.J Clin Oncol 2009; 27: 1227-1234.
58. Soria JC. Avastin in Lung Cancer - Discussant AVAiL LBA1.ESMO 2008 Presidential Symposium, ESMO meeting,Stockholm, September 12-16 2008. www.esmo.org/fileadmin/media/presentations/977/2063/LAB1DISCUSSION.ppt.pdf Date last accessed: July 16, 2010.
59. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implica-tions for antiangiogenic drugs as chemosensitizing agents.Cancer Cell 2008; 14: 263-273.
60. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
61. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in theepidermal growth factor receptor underlying responsiveness ofnon-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
62. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutationsare common in lung cancers from "never smokers" and areassociated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci USA 2004; 101: 13306-13311.
63. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFRmutations in lung cancer activate anti-apoptotic pathways.Science 2004; 305: 1163-1167.
64. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediatesphosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005; 102:3788-3793.
65. Mitsudomi T, Yatabe Y. Mutations of the epidermal growthfactor receptor gene and related genes as determinants ofepidermal growth factor receptor tyrosine kinase inhibitorssensitivity in lung cancer. Cancer Sci 2007; 98: 1817-1824.
66. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermalgrowth factor receptor in non-small cell lung cancer - search anddestroy. Eur J Cancer 2006; 42: 17-23.
67. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletionmutations of epidermal growth factor receptor are associatedwith prolonged survival in non-small cell lung cancer patientstreated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-3914.
68. Milton DT, Riely GJ, Pao W, et al. Molecular on/off switch. J ClinOncol 2006; 24: 4940-4942.
69. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation andresistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
70. Godin-Heymann N, Ulkus L, Brannigan BW, et al. The T790M"gatekeeper" mutation in EGFR mediates resistance to lowconcentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008; 7: 874-879.
71. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversibleEGFR/HER2 inhibitor highly effective in preclinical lung cancermodels. Oncogene 2008; 27: 4702-4711.
72. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplifica-tion leads to gefitinib resistance in lung cancer by activatingERBB3 signaling. Science 2007; 316: 1039-1043.
73. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG.Targeting MET as a strategy to overcome crosstalk-relatedresistance to EGFR inhibitors. Lancet Oncol 2009; 10: 709-717.
74. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib orchemotherapy for non-small-cell lung cancer with mutatedEGFR. N Engl J Med 2010; 362: 2380-2388.
75. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect keypathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
76. Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ197-209: a global randomized placebo-controlled phase II clinicaltrial of erlotinib plus ARQ 197 versus erlotinib plus placebo inpreviously treated EGFR inhibitor-naive patients with locallyadvanced or metastatic non-small cell lung cancer (NSCLC).J Clin Oncol 2010; 28: Suppl., abstract LBA7502.
77. Soda M, Choi YL, Enomoto M, et al. Identification of thetransforming EML4-ALK fusion gene in non-small-cell lungcancer. Nature 2007; 448: 561-566.
78. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical featuresand outcome of patients with non-small-cell lung cancer whoharbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
79. Choi YL, Takeuchi K, Soda M, et al. Identification of novelisoforms of the EML4-ALK transforming gene in non-small celllung cancer. Cancer Res 2008; 68: 4971-4976.
80. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oralALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: Suppl.,18s, abstract 3.
81. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study ofmaintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 499-506.
82. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study ofimmediate compared with delayed docetaxel after front-linetherapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591-598.
83. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin andgemcitabine first-line chemotherapy followed by maintenancegemcitabine or best supportive care in advanced non-small celllung cancer: a phase III trial. Lung Cancer 2006; 52: 155-163.
84. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib asmaintenance treatment in advanced non-small-cell lung cancer:a multicentre, randomised, placebo-controlled phase 3 study.Lancet Oncol 2010; 11: 521-529.
85. Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival(OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B)therapy with or without erlotinib (E) after completion ofchemotherapy (chemo) with B for first-line treatment of locallyadvanced, recurrent, or metastatic non-small cell lung cancer(NSCLC). J Clin Oncol 2010; 28: Suppl., 15s, abstract 7526.
86. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenancepemetrexed plus best supportive care versus placebo plus bestsupportive care for non-small-cell lung cancer: a randomised,double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
87. Soon YY, Stockler MR, Askie LM, et al. Duration of chemother-apy for advanced non-small-cell lung cancer: a systematicreview and meta-analysis of randomized trials. J Clin Oncol 2009; 27: 3277-3283.
88. Soon Y, Stockler MR, Boyer M, et al. Duration of chemother-apy for advanced non-small cell lung cancer: an updatedsystematic review and meta-analysis. J Clin Oncol 2008; 26:Suppl., abstract 8013.
89. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with eithergemcitabine or erlotinib versus observation with predefinedsecond-line treatment after cisplatin-gemcitabine inductionchemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase IIIstudy. J Clin Oncol 2010; 28: Suppl., 15s, abstract 7507.
90. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survivalbenefit in elderly patients with advanced non-small-cell lungcancer. J Clin Oncol 2010; 28: 2191-2197.
91. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer inelderly patients: an analysis of the surveillance, epidemiology,and end results database. J Clin Oncol 2007; 25: 5570-5577.
92. Gridelli C. The ELVIS trial: a phase III study of single-agentvinorelbine as first-line treatment in elderly patients withadvanced non-small cell lung cancer. Elderly Lung CancerVinorelbine Italian Study. Oncologist 2001; 6: Suppl. 1, 4-7.
93. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderlypatients with advanced non-small-cell lung cancer: theMulticenter Italian Lung Cancer in the Elderly Study (MILES)phase III randomized trial. J Natl Cancer Inst 2003;95: 362-372.
94. Camerini A, Valsuani C, Mazzoni F, et al. Phase II trial of single-agent oral vinorelbine in elderly (o70 years) patients withadvanced non-small-cell lung cancer and poor performancestatus. Ann Oncol 2010; 21: 1290-1295.
95. Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase IItrial of two schedules of docetaxel in elderly or poor perfor-mance status patients with advanced non-small cell lung cancer.J Thorac Oncol 2007; 2: 306-311.
96. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study ofdocetaxel compared with vinorelbine in elderly patients withadvanced non-small-cell lung cancer: results of the West JapanThoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24: 3657-3663.
97. Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versusvinorelbine in chemotherapy-naive elderly patients withadvanced non-small-cell lung cancer (INVITE): a randomized,phase II study. J Clin Oncol 2008; 26: 4253-4260.
98. Gridelli C, Kaukel E, Gregorc V, et al. Single-agent pemetrexed orsequential pemetrexed/gemcitabine as front-line treatment ofadvanced non-small cell lung cancer in elderly patients orpatients ineligible for platinum-based chemotherapy: a multi-center, randomized, phase II trial. J Thorac Oncol 2007; 2: 221-229.
99. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit fromsecond-line cytotoxic chemotherapy: a subset analysis of arandomized phase III trial of pemetrexed compared withdocetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 4405-4411.
100. Tibaldi C, Bernardini I, Chella A, et al. Second-line chemotherapywith a modified schedule of docetaxel in elderly patients withadvanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 401-405.
101. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib foradvanced non-small-cell lung cancer in the elderly: an analysisof the National Cancer Institute of Canada Clinical Trials GroupStudy BR.21. J Clin Oncol 2008; 26: 2350-2357.
102. Lang K, Marciniak MD, Faries D, et al. Trends and predictors offirst-line chemotherapy use among elderly patients withadvanced non-small cell lung cancer in the United States. LungCancer 2009; 63: 264-270.
103. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapyfor elderly patients with advanced non-small-cell lung cancer:implications of Eastern Cooperative Oncology Group 5592, arandomized trial. J Natl Cancer Inst 2002; 94: 173-181.
104. Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 620-627.
105. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25: 1553-1561.
106. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 2007; 25: 4663-4669.
107. Han K, Cao W, Che J, et al. First line chemotherapy with weeklydocetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. J ThoracOncol 2009; 4: 512-517.
108. Yoshimura N, Kudoh S, Kimura T, et al. Phase II study ofdocetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 371-375.
109. Pujol JL, Milleron B, Molinier O, et al. Weekly paclitaxelcombined with monthly carboplatin in elderly patients withadvanced non-small cell lung cancer: a multicenter phase IIstudy. J Thorac Oncol 2006; 1: 328-334.
110. Inoue A, Usui K, Ishimoto O, et al. A phase II study of weeklypaclitaxel combined with carboplatin for elderly patients withadvanced non-small cell lung cancer. Lung Cancer 2006; 52: 83-87.
111. Ramalingam S, Barstis J, Perry MC, et al. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. J Thorac Oncol 2006; 1: 240-244.
112. Sakakibara T, Inoue A, Sugawara S, et al. Randomized phase IItrial of weekly paclitaxel combined with carboplatin versusstandard paclitaxel combined with carboplatin for elderlypatients with advanced non-small-cell lung cancer. Ann Oncol 2010; 21: 795-799.
113. Hosmer W, Malin J, Wong M. Development and validation of aprediction model for the risk of developing febrile neutropeniain the first cycle of chemotherapy among elderly patients withbreast, lung, colorectal, and prostate cancer. Support Care Cancer 2010 [Epub ahead of print DOI: 10.1007/s00520-010-0821-1].
114. LeCaer H, Barlesi F, Robinet G, et al. An open multicenter phaseII trial of weekly docetaxel for advanced-stage non-small-celllung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. Lung Cancer 2007; 57: 72-78.
115. LeCaer H, Fournel P, Jullian H, et al. An open multicenter phaseII trial of docetaxel-gemcitabine in Charlson score and perfor-mance status (PS) selected elderly patients with stage IIIBpleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02astudy. Crit Rev Oncol Hematol 2007; 64: 73-81.
116. Pino MS, Gamucci T, Mansueto G, et al. A phase II study ofbiweekly paclitaxel (P) and gemcitabine (G), followed bymaintenance weekly paclitaxel in elderly patients with advancednon-small cell lung cancer (NSCLC). Lung Cancer 2008; 60:381-386.
117. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combinedwith monthly carboplatin versus single-agent therapy in patientsage 70 to 89: IFCT-0501 randomized phase III study in advancednon-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: Suppl.,18s, abstract 2.
118. Mancuso A, Migliorino M, De Santis S, et al. Correlation betweenanemia and functional/cognitive capacity in elderly lung cancerpatients treated with chemotherapy. Ann Oncol 2006; 17: 146-150.
119. Peto R, Chen ZM, Boreham J. Tobacco - the growing epidemic. Nat Med 1999; 5: 15-17.
120. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, andlung cancer in the UK since 1950: combination of nationalstatistics with two case-control studies. BMJ 2000; 321: 323-329.